• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Research

Independent equity research and analysis from our analyst team

Research

Independent equity research and analysis from our analyst team

Nightingale: We factored the project delay into our estimates
Research6/12/2026, 7:20 AM by
Antti Siltanen, Antti Luiro

Nightingale: We factored the project delay into our estimates

The revenue outlook for the next fiscal year exceeds 10 MEUR.

Nightingale Health
Puuilo Q1'26: Spot on
Research6/12/2026, 6:09 AM by
Arttu Heikura

Puuilo Q1'26: Spot on

Virtually all of the company's key metrics developed in a more positive direction.

Puuilo
Kemira: Stigende omkostninger udhuler rentabiliteten
Research6/11/2026, 5:10 AM by
Petri Gostowski

Kemira: Stigende omkostninger udhuler rentabiliteten

Kemira udstedte en nedjustering onsdag, hvilket skyldes en stigning i råvare- og transportomkostninger forårsaget af krigen i Iran.

Kemira

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Suominen: Share issue in figures, valuation still high
Research6/11/2026, 6:12 AM by
Rauli Juva

Suominen: Share issue in figures, valuation still high

We updated the impact of the share issue on our estimates, but operationally our assumptions remained unchanged.

Suominen
Hafnia (Investment case): Q1 2026 delivers strong cash flow and dividends amid geopolitical disruption
Research6/10/2026, 2:10 PM by
Rasmus Køjborg, William Jørck

Hafnia (Investment case): Q1 2026 delivers strong cash flow and dividends amid geopolitical disruption

Following Hafnia's Q1 2026 quarterly report, we have updated our investment case on the company. Our updated investment case covers the key investment reasons, risks, and valuation perspective relative to product tanker peers.

Hafnia
Sitowise Group: Divestment drops Swedish millstone
Research6/10/2026, 7:14 AM by
Olli Vilppo

Sitowise Group: Divestment drops Swedish millstone

Sitowise announced yesterday that it is selling its Swedish technical consulting operations to Sweco.

Sitowise Group
Keskisuomalainen omfattende analyse: Udbytte og den digitale omstilling i centrum af fortællingen
Extensive research6/10/2026, 4:10 AM by
Arttu Heikura

Keskisuomalainen omfattende analyse: Udbytte og den digitale omstilling i centrum af fortællingen

Investorhistorien er baseret på en vellykket digital omstilling og tilpasning af den aftagende aktivitet.

Keskisuomalainen
Duell omfattende analyse: På jagt efter et vendepunkt
Extensive research6/9/2026, 6:23 AM by
Tommi Saarinen

Duell omfattende analyse: På jagt efter et vendepunkt

Vi har opjusteret vores estimater for indeværende år, men balancesituationen forbliver stram.

Duell
Terveystalo: Optikeren søger yderligere styrker
Research6/9/2026, 4:00 AM by
Roni Peuranheimo

Terveystalo: Optikeren søger yderligere styrker

Med opkøbene af Silmäasema og Hohde er Terveystalo ved at bevæge sig fra en stabil udbyttebetaler til en mere vækstorienteret retning.

Terveystalo
Danske Bank (Investment case): Q1 2026 confirms resilient earnings as Forward '28 raises the bar
Research6/8/2026, 3:08 PM by
Rasmus Køjborg, William Jørck

Danske Bank (Investment case): Q1 2026 confirms resilient earnings as Forward '28 raises the bar

Following Danske Bank's Q1 2026 interim report, we have updated our investment case on the company. Our updated investment case covers the key investment reasons, risks, and valuation perspective relative to peers across Nordic large-cap banking.

Danske Bank
Aurora Group Intiation of Coverage: Monitoring of Northern Lights starts
Extensive research6/8/2026, 8:44 AM by
Olli Vilppo

Aurora Group Intiation of Coverage: Monitoring of Northern Lights starts

Auroora's compounder story is in its early stages, but the company's playbook for achieving ambitious targets is in order.

Auroora Group
Alexandria: Drengen har også været i sauna på Esplanaden
Research6/7/2026, 11:00 AM by
Sauli Vilén

Alexandria: Drengen har også været i sauna på Esplanaden

Alexandrias første halvår har været meget stærkt, og vores estimater er steget markant. I forhold til de forhøjede estimater er aktien billig.

Alexandria Group
Atria: Værdiansættelsen faldt til et attraktivt niveau, selvom inflationen presser på
Research6/5/2026, 5:00 AM by
Rauli Juva, Pauli Lohi

Atria: Værdiansættelsen faldt til et attraktivt niveau, selvom inflationen presser på

Som følge af kursfaldet er selskabets værdiansættelse (f.eks. 2026 P/E og EV/EBIT 9x) efter vores mening faldet til et attraktivt niveau.

Atria
Aspocomp omfattende analyse: Ny vækstfase drevet af stærk efterspørgsel
Extensive research6/4/2026, 3:48 PM by
Kaisa Vanha-Perttula

Aspocomp omfattende analyse: Ny vækstfase drevet af stærk efterspørgsel

Vi forventer, at regnskabsmeddelelsen vil vise en klar opjustering i de kommende år, men vi mener, at en betydelig del af denne udvikling allerede er indregnet i aktien.

Aspocomp Group
Metacon: Securing funding to fuel the next growth phase
Research6/4/2026, 5:57 AM by
Lucas Mattsson

Metacon: Securing funding to fuel the next growth phase

In our view, the recently announced capital raise reduces the financing risks and should give the company the runway to execute its order backlog and help convert parts of its sales pipeline, at least in the short term.

Metacon
Nightingale: Nightingale sings to a deaf market
Research6/4/2026, 6:36 AM by
Antti Siltanen

Nightingale: Nightingale sings to a deaf market

The low valuation compensates for the very high level of risk.

Nightingale Health
North Media (Investment Case): Improved Q1 profit, but lowered guidance ceiling
Research6/3/2026, 9:54 AM by
Jacob Frehr, Rasmus Køjborg

North Media (Investment Case): Improved Q1 profit, but lowered guidance ceiling

Today, we publish our updated North Media A/S investment case following the Q1 2026 report. North Media delivered improved Q1 profitability with EBIT rising to DKK 4m and EBITDA up 72%, though management cut the top end of 2026 guidance on a weak start in SDR and BoligPortal. The stock continues to trade at a significant discount to peers, as the large securities portfolio results in a very low implied EV, leaving the operating business valued at close to zero.

North Media
Martela: Flyttebyrden lettede, balancens byrde forbliver
Research6/3/2026, 6:12 AM by
Thomas Westerholm

Martela: Flyttebyrden lettede, balancens byrde forbliver

Vi har taget højde for salget af Martelas flytteserviceforretning i vores estimater, hvilket har løftet vores rapporterede resultatestimat for indeværende år, men sænket de operationelle estimater.

Martela
Herantis: Clarity on efficacy study details
Research6/3/2026, 8:21 AM by
Antti Siltanen

Herantis: Clarity on efficacy study details

The study will produce high-quality data on the safety of the Parkinson's disease drug candidate and preliminary data on its efficacy.

Herantis Pharma
Curasight (Investment Case): Four high-value read-outs on track for H2 2026
Research6/2/2026, 10:00 AM by
Michael Friis, Victor Skriver

Curasight (Investment Case): Four high-value read-outs on track for H2 2026

In connection with Curasight's Q1 2026 interim report, we have updated our Investment Case. Our investment case covers the key investment reasons, risks, and valuation perspectives.

Curasight